E2F7 and prostate adenocarcinoma: Furthermore, through the examination of the E2F7 expression pattern and its influence on patient outcomes in the TCGA-PRAD group, it was discovered that tumor samples exhibited no significant difference in E2F7 expression (Figure 3g).